Search
News & Events
300th participant recruited to crucial respiratory research programA research program, which enables over 25 important respiratory research studies to be undertaken, celebrated the recruitment of its 300th participant on 14 December 2022.
News & Events
New study to find COVID-fighting properties in existing medications thanks to national grantNearly 50 existing prescription medications already used by Australians will be tested by new research in the fight against COVID’s mutant variants.
News & Events
Community engagement vital in battle against antimicrobial resistance: Wal-yan Centre to establish reference groupThe Wal-yan Respiratory Research Centre is seeking expressions of interest from Western Australians to join an Antimicrobial Resistance (AMR) Community Reference Group, to provide vital community perspectives on the research activities into this global health concern.
News & Events
Four The Kids researchers in running for West Australian of the Year AwardsFour outstanding The Kids Research Institute Australia researchers, including Institute Director, Professor Jonathan Carapetis AM, have been named finalists in the 2021 Western Australian of the Year Awards.
News & Events
The Kids researchers named as finalists in 2021 Premier’s Science AwardsFour The Kids Research Institute Australia researchers – working across diverse fields including paediatric anaesthesia, bioinformatics, ear health, and the health impacts of biodiesel exhaust – have been named as finalists in the 2021 Premier’s Science Awards.
News & Events
The Kids Research Institute Australia researchers take out prestigious Premier’s Science AwardsThree outstanding researchers have won 2023 Premier’s Science Awards, with another inducted into the prestigious WA Science Hall of Fame.
News & Events
International clinical trial reduced lung inflammation in young kids with cystic fibrosisPromising results from an Australian-led clinical trial could drastically change the way we care for young children with cystic fibrosis (CF).
News & Events
New drug offers hope for people living with cystic fibrosisA promising new treatment pioneered in Western Australia for people with cystic fibrosis has commenced testing in a clinical trial in the United States and Australia.
Research
Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trialWe tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.
Research
Changes in airway inflammation with pseudomonas eradication in early cystic fibrosisNeutrophil elastase is a significant risk factor for structural lung disease in cystic fibrosis, and Pseudomonas aeruginosa airway infection is linked with neutrophilic inflammation and substantial respiratory morbidity. We aimed to evaluate how neutrophil elastase (NE) activity changes after P. aeruginosa eradication and influences early disease outcomes. We assessed participants in the AREST CF cohort between 2000 and 2018 who had P. aeruginosa cultured from their routine annual bronchoalveolar lavage (BAL) fluid and who underwent eradication treatment and a post eradication BAL. Factors associated with persistent P. aeruginosa infection, persistent neutrophilic inflammation following eradication and worse structural lung disease one year post-eradication were evaluated.